Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 297


Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.

Parrish C, Scott GB, Migneco G, Scott KJ, Steele LP, Ilett E, West EJ, Hall K, Selby PJ, Buchanan D, Varghese A, Cragg MS, Coffey M, Hillmen P, Melcher AA, Errington-Mais F.

Leukemia. 2015 Mar 27. doi: 10.1038/leu.2015.88. [Epub ahead of print]


Progress in Clinical Oncolytic Virus-based Therapy for Hepatocellular Carcinoma.

Jebar AH, Errington F, Vile RG, Selby PJ, Melcher AA, Griffin S.

J Gen Virol. 2015 Feb 23. pii: vir.0.000098. doi: 10.1099/vir.0.000098. [Epub ahead of print]


Cell migration in paediatric glioma; characterisation and potential therapeutic targeting.

Cockle JV, Picton S, Levesley J, Ilett E, Carcaboso AM, Short S, Steel LP, Melcher A, Lawler SE, Brüning-Richardson A.

Br J Cancer. 2015 Feb 17;112(4):693-703. doi: 10.1038/bjc.2015.16. Epub 2015 Jan 27.


Adenovirally delivered enzyme prodrug therapy with herpes simplex virus-thymidine kinase in composite tissue free flaps shows therapeutic efficacy in rat models of glioma.

Seth R, Khan AA, Pencavel TD, Wilkinson MJ, Kyula JN, Simpson G, Pandha H, Melcher A, Vile R, Harris PA, Harrington KJ.

Plast Reconstr Surg. 2015 Feb;135(2):475-87. doi: 10.1097/PRS.0000000000000878.


BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.

Roulstone V, Pedersen M, Kyula J, Mansfield D, Khan AA, McEntee G, Wilkinson M, Karapanagiotou E, Coffey M, Marais R, Jebar A, Errington-Mais F, Melcher A, Vile R, Pandha H, McLaughlin M, Harrington KJ.

Mol Ther. 2015 Jan 26. doi: 10.1038/mt.2015.15. [Epub ahead of print]


Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents.

Zaidi S, Blanchard M, Shim K, Ilett E, Rajani K, Parrish C, Boisgerault N, Kottke T, Thompson J, Celis E, Pulido J, Selby P, Pandha H, Melcher A, Harrington K, Vile R.

Mol Ther. 2014 Dec 29. doi: 10.1038/mt.2014.253. [Epub ahead of print]


Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo.

El-Sherbiny YM, Holmes TD, Wetherill LF, Black EV, Wilson EB, Phillips SL, Scott GB, Adair RA, Dave R, Scott KJ, Morgan RS, Coffey M, Toogood GJ, Melcher AA, Cook GP.

Clin Exp Immunol. 2015 Apr;180(1):98-107. doi: 10.1111/cei.12562.


Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.

Roulstone V, Khan K, Pandha HS, Rudman S, Coffey M, Gill GM, Melcher AA, Vile R, Harrington KJ, de Bono J, Spicer J.

Clin Cancer Res. 2015 Mar 15;21(6):1305-12. doi: 10.1158/1078-0432.CCR-14-1770. Epub 2014 Nov 25.


The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.

Alonso-Camino V, Rajani K, Kottke T, Rommelfanger-Konkol D, Zaidi S, Thompson J, Pulido J, Ilett E, Donnelly O, Selby P, Pandha H, Melcher A, Harrington K, Diaz RM, Vile R.

Mol Ther. 2014 Nov;22(11):1936-48. doi: 10.1038/mt.2014.134. Epub 2014 Jul 25.


Future clinical potential of oncolytic virotherapy for pediatric CNS tumors.

Cockle JV, Picton SV, Melcher A.

CNS Oncol. 2013 Jul;2(4):307-10. doi: 10.2217/cns.13.25. No abstract available.


Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.

Ilett E, Kottke T, Donnelly O, Thompson J, Willmon C, Diaz R, Zaidi S, Coffey M, Selby P, Harrington K, Pandha H, Melcher A, Vile R.

Mol Ther. 2014 Oct;22(10):1851-63. doi: 10.1038/mt.2014.118. Epub 2014 Jun 24.


Viral warfare! Front-line defence and arming the immune system against cancer using oncolytic vaccinia and other viruses.

Dave RV, Jebar AH, Jennings VA, Adair RA, West EJ, Errington-Mais F, Toogood GJ, Melcher AA.

Surgeon. 2014 Aug;12(4):210-20. doi: 10.1016/j.surge.2014.01.001. Epub 2014 Feb 4.


Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.

Kottke T, Boisgerault N, Diaz RM, Donnelly O, Rommelfanger-Konkol D, Pulido J, Thompson J, Mukhopadhyay D, Kaspar R, Coffey M, Pandha H, Melcher A, Harrington K, Selby P, Vile R.

Nat Med. 2013 Dec;19(12):1625-31. doi: 10.1038/nm.3397. Epub 2013 Nov 17.


Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.

Jennings VA, Ilett EJ, Scott KJ, West EJ, Vile R, Pandha H, Harrington K, Young A, Hall GD, Coffey M, Selby P, Errington-Mais F, Melcher AA.

Int J Cancer. 2014 Mar 1;134(5):1091-101. doi: 10.1002/ijc.28450. Epub 2013 Sep 18.


Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells.

Tai LH, Zhang J, Scott KJ, de Souza CT, Alkayyal AA, Ananth AA, Sahi S, Adair RA, Mahmoud AB, Sad S, Bell JC, Makrigiannis AP, Melcher AA, Auer RC.

Clin Cancer Res. 2013 Sep 15;19(18):5104-15. doi: 10.1158/1078-0432.CCR-13-0246. Epub 2013 Jul 23.


Live viruses to treat cancer.

Donnelly O, Harrington K, Melcher A, Pandha H.

J R Soc Med. 2013 Aug;106(8):310-4. doi: 10.1177/0141076813494196. Epub 2013 Jul 3. Review.


Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.

Boisgerault N, Kottke T, Pulido J, Thompson J, Diaz RM, Rommelfanger-Konkol D, Embry A, Saenz D, Poeschla E, Pandha H, Harrington K, Melcher A, Selby P, Vile R.

Mol Ther. 2013 Aug;21(8):1507-16. doi: 10.1038/mt.2013.116. Epub 2013 Jun 11.


Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling.

Kyula JN, Khan AA, Mansfield D, Karapanagiotou EM, McLaughlin M, Roulstone V, Zaidi S, Pencavel T, Touchefeu Y, Seth R, Chen NG, Yu YA, Zhang Q, Melcher AA, Vile RG, Pandha HS, Ajaz M, Szalay AA, Harrington KJ.

Oncogene. 2014 Mar 27;33(13):1700-12. doi: 10.1038/onc.2013.112. Epub 2013 Apr 29.


Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.

Kyula JN, Roulstone V, Karapanagiotou EM, Melcher AA, Harrington KJ.

Expert Opin Biol Ther. 2012 Dec;12(12):1669-78. doi: 10.1517/14712598.2012.745507. Review. Erratum in: Expert Opin Biol Ther. 2013 Jan;13(1):147.


Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells.

Adair RA, Scott KJ, Fraser S, Errington-Mais F, Pandha H, Coffey M, Selby P, Cook GP, Vile R, Harrington KJ, Toogood G, Melcher AA.

Int J Cancer. 2013 May 15;132(10):2327-38. doi: 10.1002/ijc.27918. Epub 2012 Nov 26.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk